NLS Pharmaceutics AG/$NLSP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NLS Pharmaceutics AG
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
Ticker
$NLSP
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Zurich, Switzerland
Employees
-
ISIN
CH1384053976
Website
NLSP Metrics
BasicAdvanced
$8.8M
-
-$2.63
-0.22
-
Price and volume
Market cap
$8.8M
Beta
-0.22
52-week high
$2.86
52-week low
$1.30
Average daily volume
444K
Financial strength
Current ratio
2.692
Quick ratio
2.558
Interest coverage (TTM)
-24.24%
Profitability
EBITDA (TTM)
-3.633
Management effectiveness
Return on assets (TTM)
-111.41%
Return on equity (TTM)
53.34%
Valuation
Price to book
-6.61
Price to tangible book (TTM)
-6.61
Price to free cash flow (TTM)
-1.008
Free cash flow yield (TTM)
-99.21%
Free cash flow per share (TTM)
-276.80%
Growth
Earnings per share change (TTM)
-79.39%
3-year earnings per share growth (CAGR)
-59.70%
NLSP News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for NLS Pharmaceutics AG stock?
NLS Pharmaceutics AG (NLSP) has a market cap of $8.8M as of June 30, 2025.
What is the P/E ratio for NLS Pharmaceutics AG stock?
The price to earnings (P/E) ratio for NLS Pharmaceutics AG (NLSP) stock is 0 as of June 30, 2025.
Does NLS Pharmaceutics AG stock pay dividends?
No, NLS Pharmaceutics AG (NLSP) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next NLS Pharmaceutics AG dividend payment date?
NLS Pharmaceutics AG (NLSP) stock does not pay dividends to its shareholders.
What is the beta indicator for NLS Pharmaceutics AG?
NLS Pharmaceutics AG (NLSP) has a beta rating of -0.22. This means that it has an inverse relation to market volatility.